Allterum Therapeutics completes Series Seed offering, builds team with addition of Philip Breitfeld as Chief Medical Officer
Allterum Therapeutics completes Series Seed offering, builds team with addition of Philip Breitfeld as Chief Medical Officer News provided by Share this article Share this article HOUSTON, Dec. 17, 2020 /PRNewswire/ -- Allterum Therapeutics, Inc. completed its $1.8 million Series Seed offering to members of the FanninDirect SM investor group. Allterum is developing a novel immunotherapy for treatment of IL7R-expressing cancers, including difficult to treat cases of pediatric acute lymphoblastic leukemia (ALL), a program which has received both Orphan Drug and Rare Pediatric Disease Designa...